-54.1%
ASTS vs MRNA
+697.5%
-751.6%
-82.5%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -8.9% | -2.2% | -6.8% | -8.8% |
| 7D | -28.6% | -12.7% | -15.9% | -28.0% |
| 30D | -43.1% | -20.7% | -22.4% | -42.2% |
| 3M | -64.2% | +46.3% | -110.5% | -64.9% |
| 6M | -74.0% | +305.2% | -379.3% | -79.6% |
| YTD | -68.0% | +561.2% | -629.2% | -80.6% |
| 1Y | -54.1% | +772.1% | -826.2% | -78.4% |
| All | -54.1% | +697.5% | -751.6% | -78.4% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling